24 March 2025 in British Journal of Radiology
To fully exploit the prospects presented by the increasing focus on biological approaches for enhancing radiotherapy outcomes, improvements in repeatability and translatability of radiobiological and preclinical studies are required. This requires the development and adoption of appropriate dosimetric standards and reproducible approaches to increase confidence in the studies, enabling inter-laboratory validation and facilitating clinical translation. An Institute of Physics and Engineering in Medicine (IPEM) working party reviewed the current status and challenges associated with dosimetry of medium-energy X-rays and make recommendations with the aim to optimize the potential clinical significance of radiobiological preclinical investigations. The paper discusses the currently available resources with technical recommendations for performing dosimetry in medium-energy X-rays, along with the consequences of lack of standardization and implications of dose inhomogeneity. It is clear that there is still a gap in understanding the needs for standardization of dosimetric aspects of preclinical and radiobiological studies. It is recommended that these radiobiology studies should be conducted in partnership with medical/radiation physicists. This collaboration ensures the correct utilization of suitable dosimetry systems, thus guaranteeing accuracy and consistency of dose delivery. Appropriate calibration and traceability to national/international standards laboratory, along with regular quality assurance of radiation devices, are paramount to reproducibility. Additionally, it is critical that experimental details and associated dosimetry are sufficiently reported to ensure accurate replication that enables reanalysis including evaluation of dose distributions. Increasing awareness among the researchers and the funding bodies was identified as a crucial step to improve translatability and appropriate resources are budgeted to increase the value for money of research proposals. The proposed recommendations will serve as a vital resource for researchers, encouraging uniformity in experimental design and improving the translatability of preclinical research to clinical settings.
23 May 2026 in British Journal of Radiology
Objectives: Spatially fractionated radiotherapy in the form of a lattice of high-dose regions within the tumor has potential to improve the therapeutic response compared to standard radiotherapy. We aimed (1) to develop and dosimetrically validate a proton pencil-beam scanning lattice radiotherapy (LRT) planning technique, (2) to compare against a photon VMAT LRT technique, and (3) to assess which clinical sites are feasible for treatment. Methods: 10 cases were selected, covering sites in the brain, neck, pelvis, abdomen and shoulder with gross tumor volumes greater than 100 cm3. LRT plans were developed for a Varian ProBeam system, aiming to deliver 20 Gy to the lattice vertices while minimizing dose to surrounding tissues. Plan-specific quality assurance (PSQA) was performed by independent Monte-Carlo calculation and physical dosimetric verification. End-to-end tests were performed using a CIRS head phantom containing EBT4 film. Plan quality was evaluated against VMAT LRT. Results: Clinically acceptable proton LRT plans were produced, delivering 16-20 Gy to the lattice vertices, a mean PTV dose of 2 Gy and satisfying organ-at-risk dose constraints. PSQA and end-to-end tests met clinical tolerances for non-LRT plans. For large target volumes, proton LRT produced lattices with a greater number of vertices than VMAT LRT. Conclusions: Proton LRT is technically viable using currently available delivery systems. Large tumors such as sarcoma are the most likely candidates for future clinical studies, but proton LRT is feasible for target volumes as small as 100 cm3. Advances in knowledge: The study demonstrates the feasibility of proton LRT for early phase clinical trials.
27 July 2026 in BMJ Open Quality
At the South West Wales Cancer Centre, breast radiotherapy accounts for 24% of the radiotherapy workload. In 2021, only 16% of patients started treatment within 14 days compared with the Welsh time-to-radiotherapy quality metric target of 80%. Delays risk poorer outcomes for patients and create inefficiencies as tasks are often batched and staff alternate between idle and peak workload periods. Earlier analysis showed that only 1%–2% of the overall breast radiotherapy pathway time was value-adding activity. Key delays occurred at several stages of the pathway, where the total duration of each stage, including time spent waiting in the queue and time actively worked on, averaged around 50% longer than scheduled. For example, CT simulation was typically scheduled for 2 days but took more than 4 days while organ at risk (OAR) delineation was scheduled for 2 days but took approximately 2.5 days. Our improvement strategy targeted these delays through: (1) expansion of the technologist plan approval (TPA) pathway, (2) introduction of daily workflow meetings and clearer, standardised planning protocols and (3) implementation of artificial intelligence (AI) auto-contouring for OAR delineation. These changes were tested using the Model for Improvement, with statistical process control monitoring of metrics plus staff feedback. The mean total radiotherapy breast pathway time from consent-to-treatment decreased from 19.5 days to 14.8 days, with patients commencing treatment within 14 days increasing from 16% to 55%. Use of the TPA pathway increased from 61% to 95% and plan queries reduced from 11% to 3%, reducing oncologist workload. Daily workflow meetings and improved protocols reduced average planning times from 4 days to 1.5 days and were valued by staff for improving workload equity and team cohesion. AI auto-contouring reduced OAR delineation from 2.3 to 0.6 days, though ongoing validation of contour quality is required.
14 September 2026 in Medical Physics
Particle minibeam therapy (PMBT) has emerged as an advanced modality within spatially fractionated radiation therapy, using the physical properties of protons, ions, and electrons to achieve superior normal tissue sparing whilst preserving spatial dose distribution at depths that are unachievable in conventional kV or MV X‐rays. As with any novel radiotherapy technique, successful translation into routine clinical practice requires robust evidence of efficacy, safety, and technical feasibility. This review presents a coordinated roadmap for the development and future implementation of PMBT, identifying the key challenges that must be addressed to enable safe and effective clinical implementation. This review highlights the interconnected nature of PMBT research and proposes the priority areas for future investigation, and the steps necessary to guide PMBT from experimental concept, towards clinical implementation. As most of the steps are relevant to all particle types, PMBT will be referred to in general, where specific particle types will be discussed where appropriate.
9 October 2026 in Communications Physics
Treatment-planning studies indicate potential dosimetric advantages of very high-energy electron (VHEE) radiotherapy for deep-seated tumours, but the dose models on which these studies rely have few experimental benchmarks above 100 MeV. Here, we report radiochromic film dosimetry of 150 and 200 MeV beams at CERN’s CLEAR facility and validate a Geant4-based GATE Monte Carlo (MC) framework. In air and water, simulations reproduced scattered-beam spot-size and percentage depth-dose trends at both energies; at 200 MeV, agreement between simulations and measurements was generally within ± 1 mm for spot size and 2–3% for percentage depth dose. Single- and seven-spot dose distributions were also measured at 200 MeV in a heterogeneous anthropomorphic head-and-neck phantom with water-equivalent and low-density foam inserts. Globally normalised 1%/1 mm gamma analysis of simulated and film-measured phantom dose distributions with a 20% low-dose threshold yielded pass rates of 98.7–99.9% for all four single-spot and both sagittal-plane seven-spot comparisons, and 81.9% and 97.0% for the two posterior-oblique seven-spot comparisons. During the phantom irradiations, estimated instantaneous per-spot dose rates exceeded 10⁸ Gy s⁻¹, providing physical dosimetry under ultra-high dose rate (UHDR) conditions relevant to future VHEE-FLASH studies. These data and the validated framework can inform VHEE treatment planning and accelerator design.